Phase 4
Completed N=114
Comparative Study Between Levobupivacaine and Ropivacaine in the Hip Fractures of the Elderly
Source: ClinicalTrials.gov NCT04773301 ↗Enrolled (actual)
114
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcomePrimary: Evaluation of the Analgesic Efficacy of Both Local Anesthetics in the Regional Block of Hip Fracture Surgery — 10; 4; 12; 14 Participants
◆ Published Evidence
Emerging
6citations · ~3 / year
Comparison of the Analgesic Efficacy between Levobupivacaine 0.25% and Ropivacaine 0.375% for PENG (Pericapsular Nerve Group) Block in the Context of Hip Fracture Surgery of Elderly Patients: A Single-Center, Randomized, and Controlled Clinical Trial.
Summary
Prospective, low-level, non-commercial intervention, comparative clinical trial (phase IV) of balanced, randomized groups, to compare the analgesic efficacy of the local anesthetics Ropivacaine and Levobupivacaine in peripheral nerve block in hip fracture surgery in the elderly .
Linked Publications
-
Comparison of the Analgesic Efficacy between Levobupivacaine 0.25% and Ropivacaine 0.375% for PENG (Pericapsular Nerve Group) Block in the Context of Hip Fracture Surgery of Elderly Patients: A Single-Center, Randomized, and Controlled Clinical Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evaluation of the Analgesic Efficacy of Both Local Anesthetics in the Regional Block of Hip Fracture Surgery |
10; 4; 12; 14; 21; 17 | — |
| SECONDARY Latency of Initiation. |
1.92; 1.68; 0.94; 0.75; 1.46; 1.04 | — |
| SECONDARY Secondary Effects Derived From the Combined Technique Described. |
— | — |
| SECONDARY Usefulness of the Chosen Analgesic Scale in Our Population, Especially in Patients With Cognitive Impairment. |
— | — |
Eligibility Criteria
Inclusion Criteria
- The patient will have to voluntarily sign and understand the informed consent that will be provided in writing.
- Patients over 65 years of age, with a hip fracture, who are going to be operated on at the Salamanca University Assistance Complex (CAUSA).
Exclusion Criteria
- Rejection of the technique.
- Allergy to any of the drugs.
- Coagulation disorders.
- Local infections instead of puncture.
- Vascular prostheses at the femoral level.
Data sourced from ClinicalTrials.gov (NCT04773301) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.